

1/25/06



PTO/SB/08B (07-05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/613,222
				Filing Date	July 3, 2003
				First Named Inventor	Joseph Rubinfeld
				Art Unit	1642
				Examiner Name	Gary B. Nickol
Sheet	1	of	1	Attorney Docket Number	12636-330.201

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		ATTADIA et al. 5-aza-2'-deoxycytidine as a differentiation inducer in hemopoietic malignancies: preliminary observations on in vivo modulation of leukemia cell phenotype and correlations with clinical response. <i>Experimental Hematology</i> . 1988; Vol. 16: 530.	
		BROWN, R. et al. Demethylation of DNA by decitabine in cancer chemotherapy. <i>Expert Rev Anticancer Ther</i> . 2004; 4(4): 501-510.	
		GILBERT, J. et al. The Clinical Application of Targeting Cancer through Histone Acetylation and Hypomethylation. <i>Clinical Cancer Research</i> . 2004; 10: 4589-4596.	
		HERMAN, J. G. et al. Gene Silencing in Cancer in Association with Promoter Hypermethylation. <i>The New England Journal of Medicine</i> . 2003; 349(21): 2042-2054.	
		KOZAR et al. Interleukin 12-based immunotherapy improves the antitumor effectiveness of a low-dose 5-aza-2'-deoxycytidine treatment in L1210 leukemia and B16F10 melanoma models in mice. <i>Clinical Cancer Research</i> . 2003; Vol. 9: 3124-3133.	
		LEONE, G. et al. DNA methylation and demethylating drugs in myelodysplastic syndromes and secondary leukemias. <i>Haematologica</i> . 2002; 87(12): 1324-1341.	
		LEONE, G. et al. Inhibitors of DNA methylation in the treatment of hematological malignancies and MDS. <i>Clin Immunol</i> . 2003; 109(1): 89-102.	

Examiner signature		Date Considered	11/20/06
--------------------	---	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

2807311_1.DOC

Attorney Docket No. 12636-330.201

11/9/06




PTO/SB/08 (07/05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/613,222
				Filing Date	July 3, 2003
				First Named Inventor	Joseph Rubinfeld
				Art Unit	1642
				Examiner Name	Laura B. Goddard
Sheet	1	Of	1	Attorney Docket Number	12636-330

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
		KANTARJIAN, et al. Chronic myelogenous leukemia - progress at the M.D. Anderson cancer center over the past two decades and future directions: first Emil J. Freireich award lecture. Clinical Cancer Research. 1997; 3:2723-2733.	
		ZAGOZDDZON, et al. Effective chemo-immunotherapy of L1210 leukemia in vivo using interleukin-12 combined with doxorubicin but not with cyclophosphamide, paclitaxel or cisplatin. Int J. Cancer. 1998; 77:720-727.	
		ZAHARKO, et al. Effects of 5-Aza-2'-deoxycytidine in combination with the biochemical modulator thymidine or the immune modulator pyran copolymer on L1210 leukemia-bearing mice. Cancer Treatment Reports. 1984; 68:1255-1264.	

Examiner Signature		Date Considered	11/20/06
--------------------	---	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

7/17/06


PTO/SB/08 (07/05)

Approved for use through 07/31/2006. OMB 0651-0031


U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/613,222
				Filing Date	July 3, 2003
				First Named Inventor	Joseph Rubinfeld
				Art Unit	1642
				Examiner Name	Laura B. Goddard
Sheet	1	Of	4	Attorney Docket Number	12636-330.201

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		US-2004/0109846	6/10/2004	Rubinfeld et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶

Examiner Signature		Date Considered	11/20/06
--------------------	---	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/613,222
				Filing Date	July 3, 2003
				First Named Inventor	Joseph Rubinfeld
				Art Unit	1642
				Examiner Name	Laura B. Goddard
Sheet	2	Of	4	Attorney Docket Number	12636-330.201

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
		BOUCHARD, et al. Incorporation of 5-Aza-2'-deoxycytidine-5'-triphosphate into DNA. Interactions with mammalian DNA polymerase alpha and DNA methylase. Mol. Pharmacol. 1983; 24:109-114.	
		BOVENZI, et al. DNA methylation of retinoic acid receptor beta in breast cancer and possible therapeutic role of 5-aza-2'-deoxycytidine. Anticancer Drugs. 1999;10:471-476.	
		CALIARO, et al. Response of four human ovarian carcinoma cell lines to all-trans retinoic acid: relationship with induction of differentiation and retinoic acid receptor expression. Int. J. Cancer 1994;56:743-748.	
		COTE, et al. Demethylation by 5-aza-2'-deoxycytidine of specific 5-methylcytosine sites in the promoter region of the retinoic acid receptor beta gene in human colon carcinoma cells. Anti-Cancer Drugs. 1998;9:743-750.	
		CROWE, D. L. Retinoic acid receptor beta induces terminal differentiation of squamous cell carcinoma lines in the absence of cyclin-dependent kinase inhibitor expression. Cancer Res. 1998;58:142-148.	
		DENG, et al. Loss of heterozygosity in normal tissue adjacent to breast carcinomas. Science. 1996; 274:2057-2059.	
		DENISSENKO, et al. Cytosine methylation determines hot spots of DNA damage in the human P53 gene. Proc. Natl. Acad. Sci. USA 1997; 94:3893-3898.	
		EHRLICH, et al. Amount and distribution of 5-methylcytosine in human DNA from different types of tissues of cells. Nucleic Acid Res. 1982; 10:2709-2721.	
		HAMEL, et al. G1 cyclins and control of the cell division cycle in normal and transformed cells. Cancer Invest. 1997;15:143-152.	
		HERMAN, et al. Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res. 1995;55:4525-4530.	

Examiner Signature		Date Considered	11/20/06
--------------------	--	-----------------	----------


*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language translation is attached.


This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known		
				Application Number	10/613,222	
				Filing Date	July 3, 2003	
				First Named Inventor	Joseph Rubinfeld	
				Art Unit	1642	
				Examiner Name	Laura B. Goddard	
Sheet	3	Of	4	Attorney Docket Number		12636-330.201

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
		HOULE, et al. Tumor-suppressive effect of the retinoic acid receptor beta in human epidermoid lung cancer cells. Proc. Natl. Acad. Sci. USA. 1993;90:985-989.	
		ISSA, et al. Increased cytosine DNA-methyltransferase activity during colon cancer progression. J. Natl. Cancer Inst. 1993;85:1235-1240.	
		JONES, et al. Cellular differentiation, cytidine analogs and DNA methylation. Cell. 1980;20:85-93.	
		JUTTERMANN, et al. Toxicity of 5-aza-2'-deoxycytidine to mammalian cells is mediated primarily by covalent trapping of DNA methyltransferase rather than DNA demethylation. Proc. Natl. Acad. Sci. USA 1994;91:11797-11801.	
		KANE, et al. Methylation of the hMLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repair-defective human tumor cell lines. Cancer Res. 1997;57:808-811.	
		KISSINGER, et al. Determination of the antileukemia agents cytarabine and azacitidine and their respective degradation products by high-performance liquid chromatography. J. Chromat. 1986; 353:309-318.	
		MODRICH, et al. Mismatch repair in replication fidelity, genetic recombination, and cancer biology. Annu. Rev. Biochem. 1996; 65:101-133.	
		MOJAVERIAN, et al. Development of an intravenous formulation for the unstable investigational cytotoxic nucleosides 5-azacytosine arabinoside (NSC 281272) and 5-azacytidine (NSC 102816). J. Pharm. Pharmacol. 1984;36:728-733.	
	MOMPARLER, R. L. Molecular, cellular and animal pharmacology of 5-aza-2'-deoxycytidine. Pharmacol Ther. 1985;30:287-99.		
		OTTAVIANO, et al. Methylation of the estrogen receptor gene CpG island marks loss of estrogen receptor expression in human breast cancer cells. Cancer Res. 1994; 54:2552-2555.	

Examiner Signature		Date Considered	11/26/06
--------------------	---	-----------------	----------


*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. *Applicant's unique citation designation number (optional). *See Kind's Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. *Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). *For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. *Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. *Applicant is to place a check mark here if English language Translation is attached.


This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/613,222
				Filing Date	July 3, 2003
				First Named Inventor	Joseph Rubinfeld
				Art Unit	1642
				Examiner Name	Laura B. Goddard
Sheet	4	Of	4	Attorney Docket Number	12636-330.201

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
		OTTERSON, et al. CDKN2 gene silencing in lung cancer by DNA hypermethylation and kinetics of p16INK4 protein induction by 5-aza 2'deoxyctidine. Oncogene 1995;11:1211-1216.	
		POMPON, et al. Reversed-phase high-performance liquid chromatography of nucleoside analogues. Simultaneous analysis of anomeric D-xylo- and D-lyxofuranonucleosides and some other D-pentofuranonucleosides. J. Chromat. 1987; 388:113-122.	
		ROODI, et al. Estrogen receptor gene analysis in estrogen receptor-positive and receptor-negative primary breast cancer. J. Natl. Cancer Inst. 1995;87:446-451.	
		SHEN, et al. The rate of hydrolytic deamination of 5-methylcytosine in double-stranded DNA. Nucleic Acid Res. 1994;22:972-976.	
		SWISSHELM, et al. Down-regulation of retinoic acid receptor beta in mammary carcinoma cell lines and its up-regulation in senescing normal mammary epithelial cells. Cell Growth Differ. 1994;5:133-141.	
		YEVIN, et al. Gene methylation patterns and expression (in DNA Methylation: Molecular Biology and Biological Significance. 1993. Basel: Birkhauser Verlag). EXS. 1993;64:523-568.	


Examiner Signature		Date Considered	11/20/06
--------------------	---	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1458, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.



Substitute for form 1449/PTO		Complete if Known			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/613,222		
		Filing Date	07/03/2003		
		First Named Inventor	Joseph RUBINFELD		
		Art Unit	1642		
		Examiner Name	Not yet assigned		
Sheet	1	of	1	Attorney Docket Number	12636-330.201

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		MOMPARLER, RICHARD L., et al., "Clinical Trial on 5-AZA-2'-Deoxycytidine in Patients with Acute Leukemia," <i>Pharmac. Ther.</i> (1985) Vol. 30: pp. 277-286	
		PETTI, MARIA CONCETTA, et al., "Pilot Study of 5-Aza-2'-Deoxycytidine (Decitabine) in the Treatment of Poor Prognosis Acute Myelogenous Leukemia Patients: Preliminary Results," <i>Leukemia</i> (1993) Vol. 7, Suppl. Monograph 1: pp. 36-41	
		RICHEL, D.L., et al., "The antileukaemic activity of 5-Aza-2 deoxycytidine (Aza-dC) in patients with relapsed and resistant leukaemia," <i>Br. J. Cancer</i> (1991) 64:144-148	
		RIVARD, GEORGES F., et al., "Phase 1 Study on 5-AZA-2'-Deoxycytidine in Children with Acute Leukemia," <i>Leukemia Research</i> (1981) Vol. 5 No. 6: pp. 453-462	
		SCHWARTSMANN, G., et al., "Decitabine (5-AZA-2'-deoxycytidine; DAC) plus daunorubicin as a first line treatment in patients with acute myeloid leukemia: preliminary observations," <i>Leukemia</i> (March 1997) Vol. 11, Suppl. 1: S28-S31	
		WIJERMANS, P., et al., "Low-Dose 5-Aza-2'-Deoxycytidine, a DNA Hypomethylating Agent, for the Treatment of High-Risk Myelodysplastic Syndrome: A Multicenter Phase II Study in Elderly Patients," <i>Journal of Clinical Oncology</i> (March 2000) Vol. 18, No. 5: pp. 956-962	
		WIJERMANS, PW, et al., "Continuous infusion of low-dose 5-Aza-2'-deoxycytidine in elderly patients with high-risk myelodysplastic syndrome," <i>Leukemia</i> (March 1997) Vol. 11, Suppl. 1: S19-S23	

Examiner signature		Date Considered	11/20/06
--------------------	--	-----------------	----------


*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). *Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.



Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/613,222
Filing Date	07/03/2003
First Named Inventor	Joseph RUBINFELD
Art Unit	1642
Examiner Name	Not yet assigned
Attorney Docket Number	12636-330.201

Sheet

1

of

4

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
		US-2002/0114809 A1	02/21/2001	Rubinfeld, et al.	
		US-2002/0136709 A1	07/31/2001	Zahner, et al.	
		US-2003/0039689 A1	04/26/2002	Chen, et al.	
		US-2003/0108588 A1	09/17/2002	Chen, et al.	
		US-2003/0147813 A1	02/07/2002	Lyons	
		US-2003/0158598 A1	01/14/2003	Ashton, et al.	
		US-2003/0229047 A1	06/05/2002	Joshi-Hangal, et al.	
		US-2004/0019036 A1	09/05/2001	Robin, et al.	
		US-4,690,918	09/01/1987	Beppu, et al.	
		US-5,736,531	12/30/1993	Von Borstel, et al.	
		US-5,968,914	10/28/1987	Von Borstel, et al.	

Examiner Signature		Date Considered	11/20/06
-----------------------	--	--------------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/613,222
				Filing Date	07/03/2003
				First Named Inventor	Joseph RUBINFELD
				Art Unit	1642
				Examiner Name	Not yet assigned
Sheet	2	of	4	Attorney Docket Number	12636-330.201

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document <small>Country Code² - Number³ - Kind Code⁴ (if known)</small>	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁵
		CS 269077	12/22/1963	Ceskoslovenska akademie ved, (Prag)		
		DE 1922702	05/03/1969	Ceskoslovenska akademie ved, (Prag)		
		DE 2105468	02/05/1971	Ceskoslovenska akademie ved, (Prag)		
		EP 286958	04/06/1988	Merck Pg		
		JP 05219974	02/13/1992	Mitsui Petrochem Ind Ltd		
		JP 2002223753	01/30/2001	Hitachi		
		JP 2002370939	06/12/2001	Taisho Pharmaceutical Co. Ltd.		
		JP 2003310293	04/26/2002	Mitsui Chemical Inc.		
		PCT/US04/22367 International Search Report	07/20/2005	SuperGen, Inc.		
		WO 93/01202	07/05/1991	Pro-Neuron, Inc.		
		WO 94/26761	05/14/1993	Pro-Neuron, Inc.		
		WO 94/27632	06/01/1993	Nycomed Pharma A/S		
		WO 96/40165	06/07/1995	Pro-Neuron, Inc.		
		WO 99/01118	07/01/1997	Artherogenics, Inc.		
		WO 00/23112	10/19/1998	Methylgene, Inc.		
		WO 00/40269	01/05/1999	Clarence Lee		
		WO 00/74634 A2	06/03/1999	AU, Jessie, L., S.		
		WO 01/79164 A2	03/21/2000	Atherogenics, Inc.		
		WO 02/47611 A2	11/28/2000	Board of Regents of the University of Texas System		
		WO 02/053138 A2	01/02/2001	Shanahan-Prendergast, Elisabeth		
Examiner Signature				Date Considered	11/20/06	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/613,222
				Filing Date	07/03/2003
				First Named Inventor	Joseph RUBINFELD
				Art Unit	1642
				Examiner Name	Not yet assigned
Sheet	3	of	4	Attorney Docket Number	12636-330.201

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ² - Number ³ - Kind Code ⁴ (if known)				
		WO 02/057425 A2	01/22/2001	Merck & Co., Inc.		
		WO 02/076486 A2	02/05/2001	Innoventus Project AB		
		WO 02/085400 A1	04/24/2001	Supergen, Inc.		
		WO 03/020252 A2	09/05/2001	Oncopharm Corporation		
		WO 03/026574 A2	09/24/2001	AU, Jessie, L. -S.		
		WO 03/046190 A1	11/30/2001	Medigene Aktiengesellschaft		
		WO 03/065995 A2	02/07/2002	SuperGen, Inc.		
		WO 03/076593 A2	03/07/2002	The Johns Hopkins University School of Medicine		
		WO 03/076594 A2	03/07/2002	The Johns Hopkins University		
		WO 2003/087774 A3	04/12/2002	Curators of the University of Missouri		
		WO 03/092623 A2	05/02/2002	Wyeth Holdings Corporation		
		WO 2004/009023 A2	07/18/2002	University of Utah Research Foundation		
Examiner Signature				Date Considered	11/20/06	


*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language translation is attached.


This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			Complete if Known		
			Application Number	10/613,222	
			Filing Date	07/03/2003	
			First Named Inventor	Joseph RUBINFELD	
			Art Unit	1642	
			Examiner Name	Not yet assigned	
Sheet	4	of	4	Attorney Docket Number	12636-330.201

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		VON HOFF, et al., "5-Azacytidine. A New Anticancer Drug With Effectiveness in Acute Myelogenous Leukemia," <i>Annals of Internal Medicine</i> (1976) 85(2), pages 237-245	

Examiner signature		Date Considered	11/20/06
--------------------	---	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. Department of Commerce

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application No.	10/613,222
				Filing Date	July 3, 2003
				First Named Inventor	Rubinfeld
				Art Unit	1645
				Examiner Name	Unassigned
Sheet	1	Of	2	Attorney Docket No.	12636-330.201

OTHER PRIOR ART - NON PATENT RELATED DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s) publisher city and/or country where published	T ²	
		Debusscher et al., Phase I-II Trial of 5-AZA-2'-Deoxycytidine in Adult Patients with Acute Leukemia, <i>Leukemia Research</i> , Vol. 5, pp. 131-142, 1981		
		Kantarjian et al, Decitabine Studies in Chronic and Acute Myelogenous Leukemia, <i>Leukemia</i> , Vol. 11, Supp. 1, pp. S35-S36, 1997.		
		Kantarjian et al., Results of Decitabine Therapy in the Accelerated and Blastic Phases of Chronic Myelogenous Leukemia, <i>Leukemia</i> , Vol. 11, Supp. 1, pp. 1617-1620, 1997.		
		Koshy et al., 2-Deoxy 5-Azacytidine and Fetal Hemoglobin Induction in Sickle Cell Anemia, <i>Blood: The Journal of The American Society of Hematology</i> , Vol. 96, No. 7, pp. 2379-2384, 2000.		
		Momparler et al, Clinical Trial on 5-AZA-2'-Deoxycytidine in Patients with Acute Leukemia, <i>Pharmac. Ther.</i> , Vol. 30, pp. 277-286, 1985.		
		Momparler et al., 5-AZA-2'-Deoxycytidine Therapy in Patients with Acute Leukemia Inhibits DNA Methylation, <i>Leukemia Research</i> , Vol. 8, No. 2, pp. 181-185, 1984.		
		Pinto et al., 5-AZA-2'-Deoxycytidine as a Differentiation Inducer in Acute Myeloid Lukaemias and Myelodysplastic Syndromes of the Elderly, <i>Bone Marrow Transplantation</i> , Vol. 4, Supp. 3, pp. 28-32, 1989.		
		Pinto et al., 5-AZA-2'-Deoxycytidine as a Differentiation Inducer in Human Hemopoietic Malignancies: Preliminary Observations on the <i>in vivo</i> Modulation of Leukemia Cell Phenotype and Correlations with Clinical Response, <i>Leukemia Research</i> , Vol. 8, pp. 143-164, 1984		
		Rivard et al., Phase I Study on 5-AZA-2'-Deoxycytidine in Children with Acute Leukemia, <i>Leukemia Research</i> , Vol. 5, No. 6, pp. 453-462, 1981.		
		Sacchi et al., Decitabine, a Hypomethylating Agent, is Active for the Treatment of Chronic Myelogenous Leukemia (CML) in Non-Lymphoid Blastic Phase (BP), <i>Blood: The Journal of The American Society of Hematology</i> , Vol. 92, No. 10, Supp. 1, pp. 252a, 1998.		
		Schwartsmann et al., (5-AZA-2'-Deoxycytidine; DAC) Plus Daunorubicin as a First Line Treatment in Patients With Acute Myeloid Leukemia: Preliminary Observations, <i>Leukemia</i> , Vol. 11, Supp. 1, pp. S28-S31, 1997.		
		Wijermans et al., Continuous Infusion of Low-Dose 5-AZA-2'-Deoxycytidine in Elderly Patients with High-Risk Myelodysplastic Syndrome, <i>Leukemia</i> , Vol. 11, Supp. 1, pp. 1-5, 1997.		
EXAMINER SIGNATURE			DATE CONSIDERED	11/20/06

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
Applicant's unique citation designation number (optional) 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.




PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0851-0031
U.S. Patent and Trademark Office: U.S. Department of Commerce

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)	Complete if Known				
	Application No.		10/613,222		
	Filing Date		July 3, 2003		
	First Named Inventor		Rubinfeld		
	Art Unit		1645		
	Examiner Name		Unassigned		
Sheet	2	Of	2	Attorney Docket No.	12636-330.201






OTHER PRIOR ART - NON PATENT RELATED DOCUMENTS			
		Wijermans et al., DNA Demethylating Therapy in MDS: The Experience with 5-AZA-2'-Deoxycytidine (Decitabine), <i>Blood: The Journal of The American Society of Hematology</i> , Vol. 94, No. 16, Supp. 1, pp. 306a, 1999	
		Wijermans et al., Low-Dose 5-AZA-2'-Deoxycytidine, a DNA Hypomethylating Agent, for the Treatment of High-Risk Myelodysplastic Syndrome: A Multicenter Phase II Study in Elderly Patients, <i>Journal of Clinical Oncology</i> , Vol. 18, No. 5, pp. 956-962, 2000.	
		Willemze et al., A Randomized Phase II Study on the Effects of 5-AZA-2'-Deoxycytidine Combined with Either Amsacrine or Idarubicin in Patients with Relapsed Acute Leukemia: an EORTC Leukemia Cooperative Group Phase II Study (06893), <i>Leukemia</i> , Vol. 11, Supp. 1, pp. S24-S27, 1997.	
		Zagonel et al., 5-AZA-2'-Deoxycytidine (Decitabine) Induces Trilineage Response in Unfavourable Myelodysplastic Syndromes, <i>Leukemia</i> , Vol. 7, Supp. 1, pp. 30-35, 1993.	
EXAMINER SIGNATURE		DATE CONSIDERED	11/20/06

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
Applicant's unique citation designation number (optional) 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

+

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Compleat If Known	
				Application No.	Unassigned
				Filing Date	Herewith
				First Named Inventor	Joseph Rubinfeld
				Art Unit	Unassigned
				Examiner Name	Unassigned
Sheet	2	Of	2	Attorney Docket No.	12636-330

OTHER PRIOR ART - NON PATENT RELATED DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s) publisher city and/or country where published	T ²
		ANZAI, et al., Synergistic Cytotoxicity with 2'-Deoxy-5-Azacytidine and Topotecan in Vitro and in Vivo, <i>Cancer Res.</i> (1992) Vol. 52, No. 8; Abstract.	
		COLOMBO et al., Antagonism of 5-aza-2'-Deoxycytidine Antileukemic Activity by Concomitant Treatment with Cytarabine, <i>Cancer Treatment Rep.</i> (1986) Vol. 70, No. 12; Abstract.	
		DORE, et al., Effects of 5-Aza-2'-Deoxycytidine and Interferon-Alpha on Differentiation and Oncogene Expression in HL-60 myeloid Leukemic Cells, <i>Anticancer Drugs</i> , (1992) Vol. 3, No. 3; Abstract.	
		KRITZ, et al.; Pilot Study of 5-Azacytidine (5-AZA) and Carboplatin (CBDCA) in Patients with Relapsed/Refractory Leukemia, <i>Am. J. Hematol</i> (1996a) Vol. 5, No. 2; Abstract.	
		LENZI, et al., <i>International Jnl. Oncology</i> (1995) Vol. 6 (2), pages 447-450.	
		MOMPARLER, et al., Effect of 5-aza-2'-Deoxycytidine and Retinoic Acid on Differentiation and C-Myc Expression in HL-60 Myeloid Leukemic Cells, <i>Cancer Lett.</i> (1990) Vol. 54, No. 1-2; Abstract.	
		PLUMB, et al., <i>Cancer Research</i> , (2000) Vol. 60 (1), pages 6039-6044.	
		SCHWARTSMANN, et al., <i>Investigational New Drugs</i> (2000) Vol. 18 (1), pages 83-91.	
		SCHWARTSMANN, et al.; Decitabine (5-Aza-2'-Deoxycytidine; DAC) Plus Daunorubicin as a First Line Treatment in Patients with Acute Myeloid Leukemia: Preliminary Observations, <i>Leukemia</i> , (1997) Vol. 11, Suppl. 1; Abstract.	
		WILLEMZE, et al., A Randomized Phase II Study on the Effects of 5-Aza-2'-Deoxycytidine Combined with Either Amsacrine or Idarubicin in Patients with Relapsed Acute Leukemia; an EORTC Leukemia Cooperative Group Phase II Study; <i>Leukemia</i> (1997) Vol. 11, Suppl. 1; Abstract.	
EXAMINER SIGNATURE			DATE CONSIDERED
			11/20/06

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.